Find information on thousands of medical conditions and prescription drugs.

Combined hyperlipidemia, familial

In medicine, combined hyperlipidemia (or -aemia) is a commonly occurring form of hypercholesterolemia (elevated cholesterol levels) characterised by increased LDL and triglyceride concentrations, often accompanied by decreased HDL. On lipoprotein electrophoresis (a test now rarely performed) is shows as a hyperlipoproteinemia type IIB. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

The elevated triglyceride levels (>5 mmol/l) are generally due to an increase in VLDL (very low density lipoprotein), a class of lipoprotein that is prone to cause atherosclerosis.

There are roughly two forms of this lipid disorder:

  • Familiar combined hyperlipidemia (FCH) is the familiar occurrence of this disorder, probably caused by polymorphisms in molecules and enzymes that participate in lipoprotein metabolism, such as ApoCII and ApoCIII and CETP (cholesterylester transferring protein).
  • Acquired combined hyperlipidemia is extremely common in patients who suffer from other diseases from the metabolic syndrome ("syndrome X", incorporating diabetes mellitus type II, hypertension, central obesity and CH). Excessive free fatty acid production by various tissues leads to increased VLDL synthesis by the liver. Initially, most VLDL is converted into LDL until this mechanism is saturated, after which VLDL levels elevate.

Both conditions are treated with fibrate drugs, which act on the peroxisome proliferator-activated receptors (PPARs), specifically PPARα, to decrease free fatty acid production. Statin drugs, especially the synthetic statins (atorvastatin and rosuvastatin) can decrease LDL levels by increasing hepatic reuptake of LDL due to increased LDL-receptor expression.

Read more at Wikipedia.org


[List your site here Free!]


Abdominal obesity and the expression of familial combined hyperlipidemia
From Nutrition Research Newsletter, 2/1/05

Abdominal obesity, measured by waist-to-hip ratio (WHR) or waist circumference, has been associated with an increased risk of type 2 diabetes, metabolic syndrome, myocardial infarction, hypertension and stroke. Simultaneous measurements of waist circumference and fasting triglycerides (TGs) have been proposed as inexpensive screening tools to identify men at elevated risk of CAD who are characterized by the atherogenic metabolic triad: hyperinsulinemia, elevated apo B, and small low-density lipoprotein.

Familial combined hyperlipidemia (FCHL) is the most frequent genetic lipid abnormality in humans, characterized by hyperlipidemia. FCHL subjects have a 5- to 10-fold increased risk of early myocardial infarction, mediated by genetic factors measured as the genetic relation to the proband, but also by abdominal obesity measured as WHR. To evaluate further the association of abdominal obesity with hyperlipidemia in relatives from well-defined FCHL families, a recent study from the Netherlands assessed the odds ratios (ORs) for the expression of hyperlipidemia in different categories of BMI, waist circumference and WHR in both FCHL relatives and spouses.

Fifty-two unrelated white FCHL index patients (probands) were discovered at the Lipid Clinic of the Utrecht Academic Hospital or the Maastricht Academic Hospital. Relatives and spouses of the probands visited the clinics, where they answered a standardized questionnaire and underwent a physical examination, which included lab work. Weight, height, and waist circumference were measured and BMI and WHR were subsequently calculated.

In total, 618 FCHL relatives and 297 spouses, representing a total of 52 families, were included in the study. In FCHL relatives, a graded, continuous effect of WHR on the prevalence of hyperlipidemia was found, ranging from 16% in the lowest WHR category to 57.6% in the highest category. In FCHL relatives, categories of BMI or waist circumference showed the same trend as found with WHR in FCHL, that is, a significant positive contribution to the prevalence of hyperlipidemia among FCHL relatives. In the whole study population, frequency of hypertriglyceridemia showed a significant interaction only between WHR categories and FCHL but predominant expression of hypertriglyceridemia was observed with higher categories of WHR in FCHL relatives but not in spouses.

The results clearly suggest that the genetic susceptibility to hyperlipidemia in FCHL has an interaction with abdominal obesity. It appears that WHR was the most informative and specific obesity marker associated with hyperlipidemia in FCHL. This knowledge is of value in genetic studies, where incomplete penetrance is an issue in the selection strategy and in medical treatment of FCHL subjects, where abdominal overweight should be addressed by weight loss strategies.

Carla J.H. van der Kallen, Christine Voors-Pette, and Tjerk W.A. de Bruin, Abdominal Obesity and Expression of Familial Combined Hyperlipidemia, Obesity Research 12(12): 2054-2060 (December 2004) [Address correspondence to Carla J.H. van der Kallen, Lab of Molecular Metabolism and Endocrinology, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The Netherlands. E-mail: c.vanderkallen@inumed.unimaas.nl]

COPYRIGHT 2005 Frost & Sullivan
COPYRIGHT 2005 Gale Group

Return to Combined hyperlipidemia, familial
Home Contact Resources Exchange Links ebay